Company Overview
Humana Inc. operates within the Healthcare sector as a provider of medical and specialty insurance products specifically designed for the United States market. The company executes its strategy through two distinct operational segments: Insurance and CenterWell, offering individual Medicare Advantage products that encompass health insurance benefits, wellness programs, and chronic care management. As a significant entity in the Healthcare Plans industry, the firm employs a workforce of 67,060 individuals to support its extensive service delivery network. The company's financial scale is substantial, reflected in a market capitalization of $20.39 billion and annualized revenue of $129.66 billion. These valuation and revenue figures indicate that Humana maintains a dominant position within its specific niche, managing a massive balance sheet and generating significant economic activity through its diversified insurance offerings.
Financial Health
Humana Inc. reported a trailing twelve-month revenue of $129.66 billion, generating net income of $1.19 billion and EBITDA of $3.57 billion during the same period. The substantial gap between the $129.66 billion in revenue and the $1.19 billion in net income reveals a high-cost operating structure typical of the insurance industry, where administrative expenses and claims ratios significantly compress profit margins relative to total sales. The company generated $1.32 billion in free cash flow, which provides it with the financial flexibility to service its debt obligations, invest in technology, or pursue strategic acquisitions without relying solely on external capital markets. Profitability analysis shows a gross margin of 14.5%, an operating margin of -1.8%, and a profit margin of 0.9%, indicating that while the company retains a small portion of revenue as bottom-line profit, it currently faces headwinds in its core operations that prevent positive operating earnings. Regarding liquidity and leverage, the firm holds $19.90 billion in cash against $13.27 billion in debt, supported by a debt-to-equity ratio of 74.81, suggesting a balance sheet that remains conservative despite the negative operating margin. The current ratio stands at 2.00, which indicates a robust short-term liquidity position where current assets are double the value of current liabilities, ensuring the ability to meet immediate obligations. Finally, the return on equity is 7.0% and the return on assets is 4.3%, metrics that reveal management's effectiveness in generating returns on the capital invested by shareholders and the total asset base, respectively.
Valuation Assessment
The stock carries a trailing P/E ratio of 17.18 and a forward P/E of 11.06, implying that the market expects a significant acceleration in earnings growth over the coming year to justify the lower multiple. The price-to-book ratio is 1.15, which indicates that the market values the company at a slight premium over its net asset book value, reflecting intangible assets or brand value not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.16 and an EV/EBITDA of 3.88, suggesting that the company is valued on a revenue basis that is very low relative to peers, while the EV/EBITDA highlights the cheap valuation relative to cash flows before interest, taxes, depreciation, and amortization. Price metrics show a 52-week high of $315.35 and a 52-week low of $163.11, providing a range within which the stock has traded, though the specific current price relative to this range is not provided in the available data. The beta value is 0.41, which means the stock exhibits low price volatility relative to the broader market, moving significantly less than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth for the company is 11.3% year-over-year, while earnings growth is listed as N/A in the available data, implying that bottom-line profitability has not yet realized growth comparable to the top line or that the metric is not currently being tracked as a positive growth driver. The company is a dividend payer with a yield of 2.1% and a payout ratio of 36.0%, indicating a conservative and sustainable dividend policy given that the payout consumes less than half of the reported earnings. The current lack of positive earnings growth combined with the low payout ratio suggests that the company may be prioritizing balance sheet strengthening or operational turnaround over aggressive dividend increases or external growth investments at this moment. Overall, Humana Inc. presents a profile characterized by strong top-line expansion and a modest but sustainable income return, albeit within a challenging operating margin environment.